{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.58 vs. cons $1.46",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Net Sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.62B vs. cons $2.63B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Gross Margin Expansion (bps YoY)",
      "prediction": "BEAT",
      "answer": "pred ~+350bps vs. cons/guide ~+300bps",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS Growth Guidance",
      "prediction": "BETTER",
      "answer": "guide ~+35-38% (~$8.60) vs. cons ~+30-35% (~$8.36 midpoint) (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Organic Net Sales Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.0% (reaffirmed 2.5-3.5% range) vs. cons ~3.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2027 Cocoa Cost Relief / EPS Recovery Commentary",
      "prediction": "BETTER",
      "answer": "guide ~increasingly confident 'outsized' EPS recovery aided by cocoa downside vs. cons cautious moderate 2027 growth view (FY2027)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A likely EPS beat plus a guidance raise (implicit via mid-year 'better read' comment and explicit cocoa tailwind commentary) should trigger upward FY26/FY27 estimate revisions from sell-side models, especially since gross-margin inflection (300bps+ Q2, 500bps+ H2) is the core re-rating catalyst investors have been waiting on since the March Investor Day; out-period math (2027 'outsized' EPS recovery year getting de-risked by falling cocoa) supports continued analyst upgrades rather than a fade, though the stock's already-strong pre-print run (+8% in the week prior) caps the magnitude of follow-through.",
  "day5_confidence": "MEDIUM"
}